Quick Answer
Regen BioPharma Inc reported Revenue (ASC 606) of $236.6 thousand for fiscal year 2025.
Regen BioPharma Inc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $236.6K | +0.0% |
| 2024 | $236.6K | +0.0% |
| 2023 | $236.6K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $59.1K | +0.0% | +0.0% |
| June 30, 2025 | $59.1K | +0.0% | +0.0% |
| March 31, 2025 | $59.1K | +0.0% | +0.0% |
| December 31, 2024 | $59.1K | +0.0% | +0.0% |
| June 30, 2024 | $59.1K | +86.7% | +0.0% |
| March 31, 2024 | $59.1K | — | -0.0% |
| December 31, 2023 | $59.1K | — | +86.7% |
| June 30, 2023 | $31.6K | — | — |
- Regen BioPharma Inc showed an increase of +0.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Regen BioPharma Inc’s revenue (asc 606) has grown by 0.0% (from $236.6 thousand to $236.6 thousand).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: